Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cyclin, putative | 0.0136 | 0.8787 | 0.5 |
Trypanosoma cruzi | cyclin, putative | 0.0136 | 0.8787 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0136 | 0.8787 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0086 | 0.378 | 0.3334 |
Echinococcus multilocularis | cyclin B | 0.0136 | 0.8787 | 1 |
Plasmodium vivax | cyclin dependent kinase 7 (cdk7), putative | 0.0118 | 0.6956 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0136 | 0.8787 | 1 |
Echinococcus multilocularis | cyclin | 0.0086 | 0.3717 | 0.2512 |
Schistosoma mansoni | cyclin B | 0.0136 | 0.8787 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0062 | 0.1276 | 0.1296 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0136 | 0.8787 | 1 |
Trichomonas vaginalis | cyclin A, putative | 0.0136 | 0.8787 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0069 | 0.2017 | 0.0986 |
Toxoplasma gondii | cell-cycle-associated protein kinase, putative | 0.011 | 0.6176 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0136 | 0.8787 | 1 |
Echinococcus granulosus | cyclin | 0.0086 | 0.3717 | 0.2512 |
Brugia malayi | Cyclin C | 0.0086 | 0.3717 | 0.213 |
Brugia malayi | cyclin-dependent kinase 7 homolog | 0.0084 | 0.3516 | 0.1878 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0136 | 0.8787 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDK7 protein kinase | 0.0076 | 0.2736 | 0.1181 |
Onchocerca volvulus | 0.0136 | 0.8787 | 0.5 | |
Trichomonas vaginalis | cyclin B, putative | 0.0069 | 0.2017 | 0.0986 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0076 | 0.2736 | 0.1062 |
Trichomonas vaginalis | cyclins, putative | 0.0069 | 0.2017 | 0.0986 |
Loa Loa (eye worm) | cyclin domain-containing protein | 0.0069 | 0.2017 | 0.0308 |
Trichomonas vaginalis | cyclin D, putative | 0.0069 | 0.2017 | 0.0986 |
Echinococcus multilocularis | cyclin dependent kinase 7 | 0.0076 | 0.2736 | 0.1062 |
Schistosoma mansoni | g1/s-specific cyclin C | 0.0086 | 0.3717 | 0.2512 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0136 | 0.8787 | 0.5 |
Leishmania major | cyclin | 0.0136 | 0.8787 | 0.5 |
Loa Loa (eye worm) | cyclin domain-containing protein | 0.0148 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0076 | 0.2736 | 0.1062 |
Entamoeba histolytica | cyclin family protein | 0.0069 | 0.2017 | 0.2154 |
Trichomonas vaginalis | cyclin D, putative | 0.0069 | 0.2017 | 0.0986 |
Trypanosoma cruzi | cyclin 6, putative | 0.0136 | 0.8787 | 0.5 |
Echinococcus granulosus | cyclin B | 0.0136 | 0.8787 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.8787 | 0.8527 |
Trichomonas vaginalis | cyclins, putative | 0.0136 | 0.8787 | 1 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0136 | 0.8787 | 0.5 |
Echinococcus multilocularis | oligomeric golgi complex subunit 3 | 0.0086 | 0.3717 | 0.2512 |
Trichomonas vaginalis | cyclins, putative | 0.0136 | 0.8787 | 1 |
Entamoeba histolytica | cyclin, putative | 0.0069 | 0.2017 | 0.2154 |
Entamoeba histolytica | cyclin, putative | 0.0136 | 0.8787 | 1 |
Plasmodium falciparum | MO15-related protein kinase | 0.0118 | 0.6956 | 1 |
Trichomonas vaginalis | cyclin B3, putative | 0.0069 | 0.2017 | 0.0986 |
Trichomonas vaginalis | cyclins, putative | 0.0136 | 0.8787 | 1 |
Echinococcus granulosus | oligomeric golgi complex subunit 3 | 0.0086 | 0.3717 | 0.2512 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0136 | 0.8787 | 0.848 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0136 | 0.8787 | 0.848 |
Loa Loa (eye worm) | cyclin C | 0.0086 | 0.3717 | 0.2372 |
Echinococcus granulosus | cyclin dependent kinase 7 | 0.0076 | 0.2736 | 0.1062 |
Trichomonas vaginalis | cyclin B, putative | 0.0136 | 0.8787 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0136 | 0.8787 | 1 |
Entamoeba histolytica | cyclin family protein | 0.0069 | 0.2017 | 0.2154 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.8787 | 0.8527 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.